Recent Updates
Recently added Catalysts

Intra-arterial Tenecteplase

Phase 2

Acute Ischemic Stroke | Small Molecules | Neurology |Roche Holding AG|Trials Updated: Sep 25, 2026

Intra-arterial Tenecteplase development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jan 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Intra-arterial Tenecteplase clinical trials

Intra-arterial Tenecteplase · 1 trial · 1 indication

Phase 2 1
NCT06781385Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion StrokeAcute Ischemic Stroke
ENROLLING BY_INVITATION40 Analytics
PHASE2ENROLLING BY_INVITATION
Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
Acute Ischemic StrokeUnlock trial analytics

Study Endpoints

Primary Endpoints

Participants with Change in Symptomatic Intracranial Hemorrhage
Hour 36

Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points.

Participants with Parenchymal Hematoma Type 1
24 Hours

Number of participants with parenchymal hematoma type 1

Participants with Parenchymal Hematoma Type 2
24 Hours

Number of participants with parenchymal hematoma type 2

30-Day Mortality Count
Day 30

Number of patients expired

90-Day Mortality Count
Day 90

Number of patients expired

Number of Grade 3 Adverse Events
Hour 24

Total number of grade 3 adverse events

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Intra-arterial TenecteplaseEXPERIMENTALFollowing endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist.
Intra-arterial SalinePLACEBO_COMPARATORFollowing endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist.

Interventions

NameTypeDescription
Intra-arterial TenecteplaseDRUGOne-time dose of intra-arterial tenecteplase post-thrombectomy
Intra-arterial SalineDRUGOne-time dose of intra-arterial saline post-thrombectomy
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patient/legally authorized representative has signed the Informed Consent Form * Ability to comply with the study protocol, in the investigator's judgment * Functionally independent (modified Rankin scale 0-2) prior to presentation * Baseline National Institutes of Health Stro...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Intra-arterial Tenecteplase

What is intra-arterial tenecteplase used for?

Intra-arterial tenecteplase is being studied for acute ischemic stroke, specifically in patients with large vessel occlusion who have undergone endovascular thrombectomy. It is delivered directly into the artery as an adjunct treatment following the clot removal procedure. The drug remains investigational and is not approved for commercial use.

Who is developing intra-arterial tenecteplase?

Roche Holding AG is developing intra-arterial tenecteplase. The company trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating this therapy in acute ischemic stroke.

What phase is intra-arterial tenecteplase in?

Intra-arterial tenecteplase is in Phase 2 clinical development. The single ongoing trial is a Phase 2 study, and no Phase 3 trials have been initiated. The drug is investigational and has not received FDA approval.

What clinical trials is intra-arterial tenecteplase in?

Intra-arterial tenecteplase is being evaluated in one clinical trial: NCT06781385, titled "Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke." The trial is currently enrolling by invitation, with a planned enrollment of 40 participants, and is being conducted in the United States.

How is the intra-arterial tenecteplase trial designed?

The Phase 2 trial NCT06781385 is a randomized, double-blind, placebo-controlled study. It plans to enroll 40 adults aged 18 years and older of all sexes. Participants must have acute ischemic stroke with large vessel occlusion and have undergone endovascular thrombectomy. Healthy volunteers are not eligible.